Expert Interview
Discussing the standard of care for prostate cancer and the recent approval of Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
Ticker(s): AZN, MRKInstitution: UT Southwestern
- Professor of Urology and Pharmacology at UT Southwestern Medical Center
- Manages 250 patients with prostate cancer and 50 with mCRPC
- Research is focused on the identification and targeting of molecular drivers of therapy resistance in innovative clinical model systems
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
